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Abstract
Cardiogenic strokes comprised 11% of all strokes and 25% of ischemic strokes. An accurate identifica-
tion of  the cause of stroke is necessary in order to prepare an adequate preventive strategy. In this review 
the confirmed and potential causes of embolic strokes are presented, which can be detected in echocar-
diography in the context of present treatment guidelines and gaps in evidence. There remains a need 
for further studies assessing the meaning of potential cardiac sources of embolism and establishment of 
rules for optimal medical prevention (antiplatelet therapy [APT] vs. oral anticoagulation [OAC]) and 
interventional procedures to reduce the incidence of ischemic strokes. Currently available data does not 
provide definitive evidence on the comparative benefits of OAC vs. APT in patients with cryptogenic 
stroke or embolic stroke of undetermined source. There is a lack of antithrombotic treatment scheme in 
the time between stroke and the completed diagnosis of potential sources of thromboembolism. (Cardiol 
J 2019; 26, 5: 438–450)
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Introduction
Approximately 1.1 million inhabitants of Eu-
rope suffera stroke each year, and ischemic stroke 
accounted for approximately 80% of cases [1, 2]. 
Although global stroke incidence is declining, rates 
observed in young adults are on the rise, thus sug-
gesting a need for strategies to improve prevention 
[2]. In addition, because of an ageing population, the 
absolute number of strokes is expected to dramati-
cally increase in coming years: by 2025, 1.5 million 
European people will suffer a stroke each year. 
Stroke is associated with increased long-term mor-
tality. Beyond vital prognosis, stroke patients are 
also at increased risk of poor outcome within the 
first year of the event including re-hospitalization 
(33%), recurrent event (7% to 13%), dementia (7% 
to 23%), mild cognitive disorder (35% to 47%), de-
pression (30% to 50%), and fatigue (35% to 92%), 
which all contribute to, and affect health related 
quality of life. Ischemic stroke is a heterogeneous 
disease with different mechanisms and etiologies 
and their specific treatments. An accurate identifi-
cation of the cause is essential in order to prepare 
an adequate preventive strategy. A substantial 
proportion of stroke risk remains unexplained [3].
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Using the Trial of Org 10172 in Acute Stroke 
Treatment (TOAST) criteria, ischemic strokes may 
be further subdivided into following types:
1. Thrombosis or embolism associated with large 
vessel atherosclerosis;
2. Embolism of cardiac origin (cardioembolic 
stroke);
3. Small blood vessel occlusion (lacunar stroke);
4. Other determined cause;
5. Undetermined (cryptogenic) cause (no cause 
identified, more than one cause, or incomplete 
investigation) [4].
The incidence of each cause is variable and 
depends on patient age, sex, race, geographic 
location, risk factors, clinical history, physical 
findings, and results of various tests. Embolism 
of cardiac origin accounts for around 15–30% of 
ischemic strokes. It is worth noting that stroke 
from a cardiac source carries a poorer outcome 
compared with other sources, having a 50% mor-
tality at 3 years. The diagnosis of a cardioembolic 
source of stroke is frequently uncertain and relies 
on the identification of a potential cardiac source 
of embolism in the absence of significant autoch-
thone cerebrovascular occlusive disease [5]. While 
a stuttering course has usually been attributed to 
atherothrombotic stroke, cardioembolic strokes can 
have a progressive course in at least one-fifth of 
cases given that emboli can recanalize, move and 
fragment after initial impaction. Rapid regression 
of symptoms (the spectacular shrinking syndrome) 
reflecting early recanalization has also been related 
to cardioembolic stroke [6].
In patients who are at risk for or have already 
had potentially embolic strokes, the primary role 
of echocardiography is to establish the existence of 
the source of embolism, determine the likelihood 
that such a source is a plausible cause of stroke 
or systemic embolism, and guide therapy in an 
individual patient. Ultimately stroke is classified 
as cryptogenic or undetermined when no cause 
is identified after a thorough study [7]. Embolic 
stroke of undetermined source (ESUS) is one-
fourth among cerebral infarction, but most of them 
could be ascribed to embolic stroke. This review 
presents the confirmed and potential causes of 
embolic strokes which can be detected in echo-
cardiography in the context of present treatment 
guidelines and gaps in evidence. There is still 
a need for further studies assessing the mean-
ing of potential cardiac sources of embolism and 
establishment of the rules of the optimal medical 
prevention (antiplatelet therapy [APT] vs. oral 
anticoagulation [OAC]) and interventional proce-
dures to reduce the incidence of ischemic strokes.
Cryptogenic stroke and ESUS 
The term cryptogenic stroke has been exten-
sively used in the literature to describe ischemic 
strokes of undetermined etiology. However, this 
does not take into account the extent and quality 
of the investigation performed or classification 
system used [8]. In the TOAST classification sys-
tem, stroke of undetermined cause may refer to 
a stroke with incomplete workup, more than one 
potential cause, or indeed no determined etiology 
after investigations are complete [9]. In 2014, 
the term ESUS, was coined by the cryptogenic 
stroke /ESUS international working group, ESUS 
refers to non-lacunar infarct (subcortical infarct 
≤ 1.5 cm on computed tomography [CT] or ≤ 2.0 cm 
on magnetic resonance imaging [MRI]) in the 
absence the following: extracranial or intracranial 
atherosclerosis causing > 50% luminal stenosis 
in the artery supplying the ischemic region, major 
cardioembolic sources permanent or paroxysmal 
atrial fibrillation (AF), sustained atrial flutter, 
intracardiac thrombus, prosthetic cardiac valve, 
atrial myxoma or other cardiac tumors, mitral 
stenosis (MS), myocardial infarction (MI) within 
the past 4 weeks, left ventricular (LV) ejection 
fraction (LVEF) < 30%, valvular vegetation’s or 
infective endocarditis (IE), and no other specific 
cause of stroke (e.g., dissection, arteritis, migraine/
vasospasm, drug misuse) [7]. Extensive evaluation 
including transesophageal echocardiography (TEE) 
and cardiac monitoring over an extended period of 
time could identify the etiology of ESUS patients. 
Although an antiplatelet drug is recommended in 
ESUS is the current guideline, clinical trials are 
ongoing to determine the efficacy of non-vitamin K 
antagonist oral anticoagulant in ESUS patients [9].
The established and potential cardiac  
reasons of ischemic stroke
Echocardiography (both, transthoracic echo-
cardiography [TTE] and TEE) is a widely used and 
versatile technique that can provide comprehen-
sive information of thromboembolic risk in patients 
with stroke [8, 9]. In many conditions more than 
one embolic source may be present (coexistence 
of embolic sources) or one cardioembolic condition 
may lead to another (interdependent of embolic 
sources). For instance, MS is associated with spon-
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taneous echocardiographic contrast, AF, clot, and 
even endocarditis. Conditions that are known to 
lead to systemic embolization are subdivided into 
high-risk and low-risk groups on the basis of their 
embolic potential and are presented in Tables 1 
and 2 [6, 8].
The established cardiac sources  
of ischemic stroke
Atrial fibrillation
Atrial fibrillation is the most common cardiac 
arrhythmias, and a major cause of morbidity and 
mortality due to cardioembolic stroke. Prevalence 
of AF increases with age, up to 15% in octogene-
rians, and continues to grow rapidly due to the 
increasing proportion of aging in the population. 
Moreover, the elderly population of today has 
a higher prevalence of predisposing conditions for 
AF, such as diabetes, heart failure, hypertension, 
and coronary heart disease [10]. Newly detected 
AF is identified in 10% of the patients who ex-
perience a stroke or a transient ischemic attack 
(TIA), and an additional 11% cases of AF are 
newly detected when patients undergo 30 days of 
continuous electrocardiographic monitoring [11].
The left atrial appendage (LAA) is the major site 
of thrombus formation in non-valvular AF. TEE is 
considered to be the gold-standard technique to 
detect LAA thrombi, with values of sensitivity and 
specificity approaching 99% [11].
In the Stroke Prevention in Atrial Fibrillation 
(SPAF) III and other trials, LAA thrombi, dense 
spontaneous echo contrast, LAA peak flow ve-
locities 20 cm/s, and complex aortic plaques were 
independently associated with increased thrombo-
embolic risk in AF patients [12].
Atrial fibrillation detection is important in 
stroke prevention, because anticoagulation is 
known to decrease stroke risk in the presence 
of this arhythmia. A meta-analysis of 50 studies 
involving more than 10,000 patients with a recent 
stroke found that 7.7% had AF on their admitting 
electrocardiogram. Within 3 weeks during and after 
hospitalization, another 16.9% were diagnosed. 
A total of 23.7% of these stroke patients had 
silent AF; that is AF diagnosed after hospital 
admission [13]. Olsen et al. [14] aimed to eval-
uate whether speckle tracking echocardiogra-
phy improves risk stratification for AF. After 
5.5 years patients who presented a composite 
of new-onset AF and ischemic stroke had sig-
nificantly reduced systolic function by LVEF and 
global longitudinal strain, however, only global 
longitudinal strain remained a significantly inde-
pendent predictor (hazard ratio [HR] 1.12, 95% 
confidence interval [CI] 1.00–1.25, p = 0.042, 
per 1% decrease) after multivariable adjustment for 
baseline predictors (age, sex, diabetes, hyperten-
sion, diastolic dysfunction, and LVEF) [14].
Table 1. The conditions with a high embolic  
potential.
The sources of intracardiac thrombi
Atrial arrhythmias:
— Valvular atrial fibrillation
— Non-valvular atrial fibrillation
— Atrial flutter
Akinetic segments and diffuse  
ventricular hypokinesia:
— Recent myocardial infarction
— Ventricular aneurysm
— Non-ischemic cardiomyopathies
Prosthetic valves and devices
Intracardiac vegetations
Myxoma
Papillary fibroelastoma
Other tumors
Intracardiac vegetations
Infective endocarditis
Marantic endocarditis
Aortic atheroma
Thromboembolism
Cholesterol crystal emboli
Table 2. The conditions with a low embolic  
potential.
Septal defects and anomalies
Patent foramen ovale
Atrial septal defect
Atrial septal aneurysm
Intracardiac calcifications
Mitral annular calcifications, mitral stenosis (mainly 
in the course of rheumatic heart disease)
Calcific aortic stenosis
Substenotic atherosclerotic plaques
Potential precursors of intracardiac thrombi
Mitral valve prolapse
Pouches of atrial septum
Enlargement of left atrium
Structures in dextral atrium like Eustachian valve  
or Chiari’s network
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Myocardial infraction  
and cardiomyopathies
Myocardial infarction and dilated cardiomyo-
pathy (DCM) are most frequently associated with 
LV thrombus formation attributable to stasis 
caused by regional or global myocardial dysfunc-
tion. From 1% to 2.5% of patients with acute MI 
suffer a stroke within 4 weeks, one-half in the first 
5 days. LV thrombus was more likely in patients 
with EF of < 40%, anterior wall MI and LV aneu-
rysm [11]. Embolic events are estimated to occur 
in 4% of patients with DCM who have a LVEF 
≤ 35%. Further, the incidence of LV thrombus 
in patients with DCM and sinus rhythm is 13%, 
and DCM may also have a high incidence of clini-
cally asymptomatic silent cerebral infarction [15]. 
Isolated LV noncompaction (LVNC) is a genetic 
cardiomyopathy characterized by prominent ven-
tricular trabeculations and deep intertrabecular 
recesses, or sinusoids, in communication with the 
LV cavity. The clinical sequelae of these deformi-
ties are the syndrome of heart failure and the risk 
for arrhythmias and stroke. The diagnostic stud-
ies for evaluation of LVNC are echocardiography, 
cardiac magnetic resonance (CMR) and cardiac CT. 
The Stöllberger et al. [16] revealed that stroke/ 
/embolism in LVNC is not always cardioembolic, 
but may also have an atherosclerotic cause. The 
CHADS2 score may be useful for clinical decision-
making about OAC for the prevention of stroke/ 
/embolism in LVNC patients [17].
Rheumatic heart disease
Rheumatic heart disease is a common cause 
of stroke in developing countries. Among pa-
tients with rheumatic heart disease, MS is the 
valve lesion most strongly associated with stroke 
and systemic embolism [18, 19]. Studies from the 
middle part of the last century found an annual 
incidence of systemic embolism among patients 
with rheumatic mitral valve disease of 1.5% to 
4.7% [20]. Reports on the association of embolic 
stroke with mitral valve prolapse have been 
inconsistent [19–21]. A population-based study 
of patients from Olmsted County, Minnesota, 
found an increased risk ratio (RR) of stroke or 
TIA among patients with mitral valve prolapse 
who were initially in sinus rhythm (RR 2.2; 95% 
CI 1.5–3.2) [21]. The presence of left atrium en-
largement and AF increase the incidence of silent 
brain infarction in patients with MS, whereas the 
presence of moderate to severe mitral regurgita-
tion decreases the incidence [21].
Endocarditis
Stroke often complicates IE, affecting 16–25% 
of patients with IE [21].
Most diagnoses of stroke and IE are made 
close together in time, but a period of heightened 
stroke risk becomes apparent several months be-
fore the diagnosis of IE and lasts for several months 
afterward [22, 23]. In the study of Merkler et al. 
[24] among 17,926 patients with IE, 2,275 strokes 
occurred within the 12-month period surrounding 
the diagnosis of IE.
The risk of stroke was highest in the month 
after diagnosis of IE (1,640 vs. 17 strokes in the 
corresponding month 2 years prior) [24]. A tran-
sthoracic echocardiography must be performed in 
every case of suspected IE. Vegetations (infected 
tissue mass) appear as irregular echogenic masses 
usually attached to the atrial side of the atrioven-
tricular valves or the ventricular side of the semi-
lunar valves along the line of leaflet coaptation. The 
vegetations are seen to move independently to the 
underlying valve motion [15]. IE requires admin-
istration of systemic antibiotics and, if indicated, 
surgery. Non-bacterial thrombotic endocarditis 
(NBTE), ormarantic endocarditis, is composed of 
small, sterileplatelet — fibrin vegetations on the 
cardiac valves. There is little inflammatory reac-
tion at the foot of the growth so the thrombi detach 
easily, causing multiorgan infarcts. The pathogen-
esis of NBTE is not completely understood. It is 
particularly associated with adenocarcinomas of the 
gastrointestinal tract and lungs and mechanisms 
are considered to be similar to the ones underly-
ing cancer hypercoagulability [21, 23]. A clinical 
triad of a known disease process associated with 
NBTE, heart murmur and signs of multiple sys-
temic emboli should alert the physician to NBTE. 
NBTE could be treated with tumor-suppressive, 
antiretroviral, or immunosuppressive therapy with 
systemic anticoagulation, preferably heparin-based 
however treatment options are limited because of 
Disseminated Intravascular Coagulation which is 
often present.
Fibrous and fibrinous lesions of the heart 
valves and endocardium traditionally occur in 
patients with systemic lupus erythematosus (Lib-
man-Sacks endocarditis), antiphospholipid antibody 
syndrome. Fibrin-platelet aggregates may attach to 
these fibrous and fibrinous lesions [23, 24].
Cardiac tumors
Primary tumors of the heart are rare with the 
incidence of 0.02–0.05% [25].
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The majority of them are myxomas, account-
ing for only 0.02% of primary tumors, and 75% of 
them are benign. Embolic manifestations occur in 
20–45% of patients with a cardiac myxoma, some-
times as the onset symptom [26]. From 75% to 80% 
of myxomas are located in the left atrium. Myxomas 
arising from the right ventricle are extremely rare. 
Most cases (90%) of atrial myxoma are sporadic 
with no known cause. In the remaining (10%), 
a familial pattern occurs having an autosomal domi-
nant pattern known as Carney complex which is 
characterized by multiple tumors, including atrial 
and extracardiac myxomas, cutaneous spotty pig-
mentation, non-myxomatous extracardiac tumors, 
schwannomas and various endocrine tumors, 
through a causative mutation of the PRKAR1a 
gene located on the long arm of chromosome 
17 [25]. Cardiac myxomas produce interleukin 
(IL)-6, leading to constitutional manifestations 
such as recurrent fever, anemia, arthralgia, and 
weight loss which disappear after removal of the 
tumor [26, 27]. Myxomas are frequently found 
particularly between the third and sixth decades of 
life. There are 2 types of cardiac myxomas: friable 
polypoid type and smooth-surface rounded type. 
The polypoidal type tends to result in embolism 
because of its friable consistency and intracavitary 
location [28]. Furthermore, the LV has a higher 
risk of embolization resulting from  high mobility 
and pressure in it [29, 30]. The second most com-
mon benign primary tumor of the heart is papillary 
fibroelastoma. Its prevalence is 0.002% to 0.28% 
among the general population. The average age at 
diagnosis is 56, with a primarily male preponder-
ance (58%). These kinds of tumors are often found 
on cardiac valvular surfaces. The clinical presenta-
tion of fibroelastoma varies widely, ranging from 
clinically asymptomatic to severe thromboem-
bolic events. It is important to differentiate fi-
broelastomas from cardiac myxomas and thrombi 
because of differences in their medical treatment. 
A clear surgical margin is necessary for excision of 
a myxoma due to its high rate of recurrence. On the 
other hand, fibroelastomas rarely recur after resec-
tion, thus it is recommended to preserve valvular 
function by shaving off the tumor [25]. Diagnosis at 
present is established most appropriately with two 
dimensional echocardiography. CMR can help out in 
demarcating tumor size, attachment and its mobil-
ity and this information may be further used during 
surgical resection. Positron emission tomography 
scan has been useful in identifying cardiac involve-
ment in patients with metastatic tumors and atrial 
myxoma [29]. Although, since tumor fragments 
may embolise, early anticoagulation may not be 
protective in reducing disability and mortality [30]. 
Prompt excision using cardiopulmonary bypass, 
first carried out by Crafoord in 1954, has been es-
tablished as the only acceptable mode of treatment 
for these tumors. The results of surgical resection 
are generally very good, with most series reporting 
an operative death rate of < 5%.
Potential sources of thromboembolism
Patent foramen ovale  
and atrial septal defect
Patent foramen ovale (PFO) is the most com-
mon congenital cardiac abnormality present in 
approximately 25% of the population and is respon-
sible for up to 95% of right-to-left shunts (Fig. 1). 
PFO is a communication across the interatrial 
septum between a nonadherent septum primum 
and septum secundum and is considered to be 
a risk factor for serious clinical syndromes including 
paradoxical systemic embolism such as embolic 
strokes, MI, decompression sickness in divers, 
and complications of pulmonary embolism [27]. 
PFO prevalence among patients with cryptogenic 
stroke are typically high with median prevalence of 
approximately 40% and more commonly present in 
young people. Saline contrast injection or agitated 
saline mixed with air (also referred to as a “bubble 
study”) during TTE or TEE can detect a PFO if 
microbubbles which are seen within the left atrial 
chamber within three cardiac cycles after right 
atrial opacification [8]. In situ thrombus formation 
and propensity for cardiac arrhythmias in patients 
with PFO have been suggested stroke mechanisms 
[1]. No association has been documented between 
shunt amount and stroke recurrence. Until now, 
whether PFO is a risk factor for stroke has been 
unsettled. In the SISIFO study — a multicenter, 
prospective, single-wave, cross-sectional sur-
vey conducted on 1,130 consecutive patients 
with acute ischemic stroke admitted to selected 
clinical centres underline PFO alone must not be 
considered a significant independent predictor 
for stroke; so the presence of PFO alone doesn’t 
permit rushed causal correlations or ‘therapeutic 
aggressiveness’ [31]. By far, paradoxical emboliza-
tion is the most commonly proposed mechanism 
for stroke in PFO patients. Therefore, finding 
a proximal source such as a deep venous thrombus is 
warranted, otherwise the association is rendered 
theoretical. Besides PFO closure did not prevent 
stroke. Clinical conditions such as deep vein 
thrombosis, a prolonged immobility/postopera-
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tive period, and the Valsalva maneuver were also 
not associated with embolism recurrence. Taken 
together, a mechanism other than paradoxical 
embolism may contribute to the development of 
embolic stroke in patients with PFO [32–34]. The 
probability of having a PFO as a possible cause of 
stroke in cryptogenic stroke patients may vary ac-
cording to patient characteristics [35, 36]. Several 
factors possibly associated with increased risk of 
stroke recurrence in patients with PFO include 
a right-to-left shunt detectable in resting conditions, 
amount of right-to-left shunt under Valsalva, and 
a combination of PFO with either atrial septal aneu- 
rysm (ASA) or increased interatrial septal mobility 
(Fig. 1) [37–39]. Several clinical and brain imaging 
features, including the 10-point Risk of Paradoxical 
Embolism (RoPE) score, have been suggested to 
determine a high-risk PFO (Table 3) [39]. 
Substenotic atherosclerotic plaques
Substenotic atherosclerotic plaques can pos-
sibly cause ischemic stroke by plaque rupture 
and artery-to-artery embolization. In particular, 
complicated atherosclerotic plaques with evidence 
of intraplaque hemorrhage on imaging have been 
suggested to be a potential mechanism in ESUS [7].
There are more potential causes of cardiac 
strokes, which are not entirely examined as:
 — pouches of atrial septum;
 — structures in dextral atrium like Eustachian 
valve (EV) or Chiari’s network (CN);
 — enlargement of left atrium;
 — ASA.
Pouches of left atrial septum
The left atrial septal pouch (LASP) was 
described in 2010 by Krishnan and Salazar as 
Figure 1. A. Transesophageal echocardiography (TEE), atrial septal aneurysm (ASA), patent foramen ovale (PFO) 
and atrial septal defect (ASD) in patient after ischemic stroke; B. TEE. The left atrial septal pouch (LASP) and mobile 
thrombus in right atrium (RA).
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a potential source of embolism. Some data suggest 
that when a foramen ovale closes spontaneously, 
the septum primum and the septum secundum fuse 
initially at the caudal limit of the zone of overlap of 
the two structures (Fig. 2). This incomplete fusion 
results in a pouch that, in the majority of instances, 
communicates with the left atrium cavity [40]. The 
presence of LASP with access to the systemic 
circulation also raises the possibility that, similar 
to the LAA, during low-flow states, this pouch 
might serve as a site for thrombus formation and 
embolization. But the results of clinical studies are 
inconclusive [30].
In a case-control study of relatively older 
subjects (mean age 69 years), Tugcu et al. [33] 
found that LASP was not associated with ischemic 
or cryptogenic strokes. Negative results between 
LASP and cryptogenic stroke were also reported 
in a cohort study of 566 consecutive patients 
undergoing TEE by Wayangankar et al. [34]. The 
same author also carried out a retrospective case-
control study in patients with a high prevalence 
of cardiovascular risk factors. The prevalence of 
LASP was 18%, irrespective of age or pathology. 
Their study did not show any association between 
LASP and ischemic stroke or cryptogenic stroke 
[35]. On the other hand, Wong et al. [35] studied 
212 consecutive TEE patients with mean age 
57 years and found an increased prevalence of LASP 
among cryptogenic stroke patients compared to is-
chemic stroke patients of other subtypes. Sun et al. 
[31] demonstrated among 324 patients, evidence of 
an association between LASP and ischemic stroke 
in either univariable analysis and after adjust-
ment for other stroke risk factors using multiple 
logistic regression analysis. The risk of ischemic 
stroke in this study was two- fold among patients 
with LASP than cases without LASP. Additional 
investigation should take place to determine the 
clinical significance of LASP and what interven-
tions are required to prevent ischemic stroke in 
at-risk individuals [31].
The Eustachian valve 
The EV is a remnant of the embryonic right 
valve of the sinus venosus. Embryologically, the 
EV directs oxygenated blood from the inferior vena 
cava across the PFO into the systemic circulation. 
By directing the blood from the inferior cava to the 
interatrial septum, a persisting EV may prevent 
spontaneous closure of PFO after birth and may, 
therefore, indirectly predispose one to paradoxical 
embolism. However, there have been relatively few 
studies performed looking at stroke risk in this 
population and not all authors agree that promi-
nent EV predisposes to additional risk. In a study 
by Schuchlenz et al. [36] the mean EV size was 
1.0 ± 0.4 cm; 70% of patients with an EV had a PFO 
(p < 0.001). In contrast the prevalence of PFO 
in the control group was 30% and 61% for those 
with presumed paradoxical embolism (p < 0.001). 
Thus, an EV was significantly more common for 
patients with presumed paradoxical embolism than 
in control patients (143 of 211 — 68% vs. 31 of 95 
— 33%, respectively, p < 0.001) [36].
The Vale et al. [37] investigated the relation-
ship between EV length and atrial septal movement 
in 72 consecutive patients referred to their centre 
for PFO closure following presumed cryptogenic 
stroke. The authors proposed that while a large 
degree of atrial septal movement significantly 
increases propensity to cerebral embolism in pa-
tients with PFO, its absence does not negate this 
risk. They have shown that long EV may function 
Table 3. Ten-point risk of paradoxical embolism 
(RopE) score to determine a high-risk patent  
foramen ovale (PFO).
Characteristic Points
No history of hypertension +1
No history of diabetes +1
No history of stroke or TIA +1
Nonsmoker +1
Cortical infarct on imaging +1
Age [years]:
18–29 +5
30–39 +4
40–49 +3
50–59 +2
60–69 +1
≥ 70 0
SCORE INTERPRETATION
RoPE  
score
PFO-attributable 
fraction  
(95% CI)
Estimated stroke/ 
/TIA recurrence  
at 2 years
0–3 0% (0–4) 20% (12–28)
4 38% (25–48) 12% (6–18)
5 34% (21–45) 7% (3–11)
6 62% (54–68) 8% (4–12)
7 72% (66–76) 6% (2–10)
8 84% (79–87) 6% (2–10)
9–10 88% (83–91) 2% (0–4)
CI — confidence interval; TIA — transient ischemic attack
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independently from atrial septal movement to 
potentiate paradoxical embolism [37]. 
Chiari network
The CN, present in approximately 2% of the 
population, and is a reticulated network of fibers 
originating from the Eustachian connecting to dif-
ferent parts of the right atrium. Its presence results 
from incomplete reabsorption of the right valve 
of the sinus venosus [41]. CN is often clinically 
insignificant. However, it has been reported to be 
involved in the pathogenesis of thromboembolic 
disease, endocarditis, arrhythmias, and entrap-
ment of catheters upon percutaneous intervention 
[42]. The network is associated with PFO in 80% 
of cases. The role of a CN in the pathogenesis of 
stroke is discussed. CN may create turbulent blood 
flow leading to thrombus formation. The fibers of 
the network are sometimes torn during life and 
may break free. The fenestrated types may rarely 
remove emboli from the circulation, but this is 
purely by chance, and further emboli are likely 
to reach the lung [38]. Rigatelli et al. [39] during 
over a 24-month period, prospectively enrolled 
50 consecutive patients (mean age 37 ± 12.5 years, 
38 females) with previous stroke and migraine 
referred for PFO catheter-based closure. Patients 
with EV and CN had more frequently a curtain 
pattern on transcranical Doppler, a larger right-
to-left shunt, more recurrent cerebral paradoxical 
embolism before closure, and a higher preoperative 
MIDAS score. This study suggests that EV and 
CN have a deep impact on migraine with aura and 
paradoxical embolism pathophysiology: EV, CN, 
and migraine with aura should be considered as 
adjunctive risk factors for paradoxical embolism 
in the work-up of both symptomatic and asympto-
matic PFO patients [39].
The left atrial enlargement
Little is known about the risk of stroke as-
sociated with left atrial enlargement in patients 
in sinus rhythm, and whether such patients may 
need a thromboprophylaxis. Formal stroke risk 
stratification among patients with left atrial en-
largement may further help to identify patients 
who stand to gain from preventive antithrombotic 
therapy [43]. The normal left atrial volume index 
(LAVI) using echocardiography is 22 ± 6 mL/m2; 
thus, on the basis of the sensitivity and specificity 
Figure 2. Diagnostic algorithm for cardiac workup of ischemic stroke. AF — atrial fibrillation; CT — computed tomo-
graphy; ECG — electrocardiography; ESUS — stroke of undetermined source; MRI — magnetic resonance imaging; 
USG — ultrasonography; TEE — transesophageal echocardiography; TTE — transthoracic echocardiography.
All patients with ESUS:
— History + physical examination + neurological assessment
— MRI or CT scanning of the brain
— ECG + chest ray + laboratory test
— Ultrasound or MRI/CT angiography of extracranial carotid arteries
— Transcranical Doppler USG
— ECG cardiac monitoring for at least 72 h
— TTE
No cardiac sources suspected Cardiac sources suspected
Other etiologies:
— Lacunar stroke
— Atherothrombotic stroke
— Hemodynamic stroke
— Thrombotic stroke
Hypercoagulable state test:
— Protein C
— Protein S
— Antiphospholipid antibodies
— Leiden mutation
— Hyperhomocystein
— Antythrombin III
TEE, if negative — TTE
Additional ECG monitoring by long-term non-invasive 
ECG monitors or implanted loop redcorders if high  
suspicion of paroxysmal AF
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for predicting cardiac events [3, 6–8], the American 
Society of Echocardiography (ASE) considers left 
atrial enlargement as > 28 mL/m2 (i.e., 1 SD from 
the mean). However, for the purpose of identify-
ing LV diastolic dysfunction, an LAVI cut point 
> 34 mL/m2 (i.e., 2 SD) was endorsed in both ASE 
and the European Association of Echocardiogra-
phy guideline document [26]. Biteker et al. [44] 
prospectively followed 310 consecutive first-ever 
acute ischemic stroke patients aged 50 years or 
older who were admitted to hospital within 24 h 
of the onset of stroke symptoms. The optimal cut 
off value, sensitivity, and specificity of LAVI to 
distinguish cardioembolic stroke from non-cardi-
oembolic stroke were 30 mL/m2 (81% and 64%, 
respectively). Kaplan-Meier analysis showed that 
there was a stepwise increase in risk of mortality 
with each increment of LAVI category. Overvad et 
al. [40] identified nine cohort studies and analyzed 
a total of 67,875 participants and 3,093 stroke 
outcomes. All studies reported a higher risk of 
stroke with larger/enlarged left atrium compared 
to smaller/normal sized left atrium. The underly-
ing etiology explaining this observed higher risk 
is likely to be multifactorial and not confined to 
a potential direct effect of left atrial enlargement 
on thromboembolic risk [44]. In the study of Yaghi 
et al. [41] in 655 first ischemic stroke patients over 
a median of 4 years, there were 65 recurrent 
ischemic strokes (29 were cardioembolic or cryp-
togenic). In multivariable models adjusted for 
confounders, including AF and heart failure, mod-
erate-severe left atrial enlargement  compared with 
normal left atrial size was associated with greater 
risk of recurrent cardioembolic/cryptogenic stroke, 
but not total ischemic stroke [42].
Left atrial dysfunction has been reported in 
patients with PFO. It is postulated that left atrial 
dysfunction could be involved in the development 
of an arterial embolism in patients with PFO [43]. 
One hypothesis is that a pathological PFO might 
contribute to atrial enlargement.  In contrast, 
another possibility is that cardiac thrombus that 
is secondary to left atrial enlargement might be 
a determinant of stroke and PFO is additive or 
even incidental.
Atrial septal aneurysm 
An ASA consists of redundant atrial septal 
tissue bulging into the right or the left atrium 
(Fig. 1). Some studies indicate that existence of 
ASA may be a potential risk factor of stroke. In 
patients with ASA and a history of embolic events, 
ASA may enhance migration of a thrombus con-
stituted in situ or transiting through it. Marked 
mobility of ASA may also increase the risk of 
peripheral embolus. Rigatelli et al. [39] revealed 
that moderate-to-severe ASA might be associated 
with left atrial dysfunction in patients with PFO. In 
the majority of cases ASA is associated with other 
cardiac abnormalities such as PFO and atrial septal 
defects as well as mitral valve prolapse or atrial ar-
rhythmias. Mattioli et al. [22] have demonstrated 
a statistical association between PFO and ASA and 
have shown that both morphological abnormalities 
were independent predictors of embolic events in 
a multivariate analysis [44].
Anticoagulation affairs and stroke risk
Acetylsalicylic acid, clopidogrel, or the com-
bination of acetylsalicylic acid and dipyridamole, 
are all acceptable options for secondary preven-
tion in patients with ischemic stroke or TIA of 
arterial origin [45]. Currently, OAC therapy with 
warfarin or one of the non-vitamin K antagonist 
oral anticoagulants (NOACs), including a direct 
thrombin inhibitor (dabigatran) and factor Xa inhibi-
tors (rivaroxaban, apixaban, and edoxaban) is the 
most effective prophylactic approach available to 
patients with AF at high risk of thromboembolic 
events. Contemporary guidelines from the Euro-
pean Society of Cardiology, the American College of 
Cardiology, the American Heart Association (AHA), 
and the Heart Rhythm Society for managing stroke 
prophylactic treatment in AF patients advocate for 
the use of the CHA2DS2-VASc score (Congestive 
heart failure [1 point], Hypertension [1 point], 
Age 75 years [2 points], Diabetes [1 point], Stroke 
[2 points], Vascular disease [1 point], Age 65–74 
years [1 point], and female sex category [1 point]) 
for stroke risk stratification [46, 47]. In ‘low risk’ 
patients with no additional stroke risk factors, oral 
anticoagulant treatment is not recommended. The 
United States guideline offers a Class IIb recom-
mendation on either no treatment, acetylsalicylic 
acid therapy, or oral anticoagulant treatment in 
AF patients with a CHA2DS2-VASc score of 1. The 
European guideline recommends that female sex 
as a single risk factor should be disregarded, and 
hence, low risk is defined as a CHA2DS2-VASc score 
of 0 in males, 1 in females, where no antithrombotic 
therapy is recommended [48, 49]. Thus, oral an-
ticoagulant treatment should be considered in AF 
patients with a one stroke risk factor (i.e. CHA2DS2-
-VASc score of 1 in males, or 2 for females; Class IIa 
recommendation), or recommended in those with 
a CHA2DS2-VASc score ≥ 2 (Class I recommendation) 
[50, 51]. Patients with mechanical valve prosthesis 
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and with AF and moderate or severe MS should 
be treated with vitamin K antagonist. There is 
a high risk of stroke and systemic thromboembolism 
but also a high risk of bleeding if anticoagulants 
are prescribed. Newer surgical or percutaneous 
interventions (WATCHMAN, LARIAT, and Am-
platzer devices) have been developed for stroke 
prevention in patients with AF. These devices are 
typically used in AF patients who have high risk 
for thromboembolic events and cannot tolerate 
prolonged anticoagulation therapy. Although these 
interventions have shown feasibility, their long-
term superiority to medical management remains 
a matter of debate [12]. The cryptogenic strokes are 
being recognized as sharing many characteristics 
with cardioembolic strokes [4]. The major chal-
lenge in supervising stroke is secondary stroke 
prevention of cryptogenic strokes, especially in 
choosing antithrombotic therapy [4]. A relatively 
frequent complication of ischemic stroke is hemor-
rhagic transformation. It happens in 2.2% to 44% 
of clinical cases [51].There has been no definitive 
study assessing the comparative effectiveness of 
OAC vs. APT in this population. Currently available 
data do not provide definitive evidence on the com-
parative benefits of OAC vs. APT in patients with 
cryptogenic stroke or ESUS [44]. There are ongo-
ing studies assessing advantages and disadvantages 
of these two kinds of therapies. The Randomized, 
double-blind, Evaluation in secondary Stroke Pre-
vention comparing the EfficaCy and safety of the 
oral Thrombin inhibitor dabigatran etexilate vs. 
acetylsalicylic acid in patients with Embolic Stroke 
of Undetermined Source (RE-SPECT ESUS) is 
a prospective, randomized, double-blind, multicenter 
trial involving approximately 6000 patients and 550 
centers. Subjects are randomized to dabigatran or 
acetylsalicylic acid and are treated for an expected 
minimum of 6-months and for up to approximately 
3 years. The primary efficacy outcome is a time to 
first recurrent stroke (ischemic, hemorrhagic, or 
unspecified). Key secondary outcomes are time to 
first ischemic stroke and time to first occurrence 
in the composite outcome of nonfatal stroke, non-
fatal MI, and cardiovascular death. The primary 
safety outcome is major hemorrhage, including 
symptomatic intracranial hemorrhage [50]. The 
ATTICUS randomized trial is designed to deter-
mine whether the factor Xa inhibitor apixaban 
administered within 7 days after ESUS, is supe-
rior to acetylsalicylic acid for prevention of new 
ischemic lesions documented by brain MRI within 
12 months after index stroke. The primary outcome 
is the occurrence of at least one new ischemic le-
sion identified by axial T2-weighted FLAIR MRI 
and/or axial diffusion-weighted imaging MRI at 
12 months when compared with the baseline MRI. 
Key secondary outcomes are the combination of 
recurrent ischemic strokes, hemorrhagic strokes, 
and systemic embolism [52].
The New Approach riVaroxaban Inhibition of 
Factor Xa in a Global trial versus ASA to prevent 
Embolism in ESUS (NAVIGATE ESUS) is a multi-
national, randomized, double-blind, superiority trial 
comparing antithrombotic therapies for second-
ary stroke prevention in a well-defined cohort of 
patients with nonlacunar cryptogenic stroke with 
embolic features. Main results are anticipated in 
2018.
There is a possibility that a covert AF is the 
underlying pathogenesis in ≈40% of ESUS patients. 
In this context the present antithrombotic strategy 
might be suboptimal, which in turn could have 
important consequences on their outcome. Indeed, 
the reduced risk of ischemic stroke in response to 
warfarin is offset by a risk of hemorrhage in patients 
with reduced LVEF [51]. Therefore, it is not clear 
whether patients with sinus rhythm and reduced 
LV function should be treated with anticoagula-
tion therapy during or after treatment for heart 
failure [53]. The ACCF/AHA guidelines for the 
management of valvular heart disease recommend 
acetylsalicylic acid therapy for patients with mitral 
valve prolapse who experience TIAs (Class I; Level 
of evidence C) and warfarin for these patients with 
a history of stroke and mitral regurgitation, AF, or 
left atrial thrombus (Class I; Level of evidence C). 
There is no evidence that anticoagulant therapy 
reduces the risk of stroke in patients with mitral 
annular calcification (MAC) [21]. The decision to 
use antiplatelet agents vs. anticoagulants in pa-
tients with MAC should include the consideration 
of other potential comorbid factors such as: AF 
(that can occur 12 times more often in patients 
with MAC in comparison to those without MAC) 
or endocarditics [26, 53]. Current evidence-based 
guidelines do not support routine closure of PFO in 
the absence of deep venous thrombus or proximal 
source and recommend antiplatelet therapy. Three 
major randomized controlled trials did not show 
a net benefit from closure of PFO in this popula-
tion. A meta-analysis evaluating these 3 and an 
additional 11 non-randomized observational stud-
ies failed to prove superiority of closure against 
medical therapy, with an increased incidence of new 
onset AF in the closure group (RR 3.50). However, 
it should be noted that previous PFO closure trials 
differed in study criteria, devices used, and lack of 
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standardized design. Ongoing trials will hopefully 
find which patients are ideal for PFO closure. At 
the present time, patients should be thoroughly 
evaluated and risk stratified before considering 
closure of PFO in ESUS [52]. Furthermore, cur-
rent evidence-based guidelines do not recommend 
anticoagulation over APT in patients with PFO. 
A large randomized control trial evaluating outcomes 
in PFO patients with anticoagulation vs. APT with 
acetylsalicylic acid reported a 2-year event rates 
of 9.5% in the warfarin-treated group and 17.9% in 
the acetylsalicylic acid-treated group, but could not 
conclude statistical significance (HR 0.5; 95% CI 
0.2–1.7). In addition, there was no significant dif-
ference between patients with isolated PFO, those 
associated with an atrial septal defect, or among 
small or large PFO’s. More recently, an individual 
participant meta-analysis evaluating OAC or APT 
in 2385 patients found no statistically significant 
difference in recurrent stroke, TIA, death; or stroke 
alone. Furthermore, subgroup analysis did not find 
significant heterogeneity of treatment effects in 
both groups, supporting the finding [8, 53]. Patients 
with cryptogenic strokes should be evaluated for 
the presence of venous thromboembolism. If ve-
nous thromboembolism is present, treatment is the 
same as for pulmonary embolism: anticoagulation. 
If venous thromboembolism is not present, APT 
is indicated [54]. 
Conclusions
About 80% of ischemic strokes occur in per-
sons without AF, and it is therefore important to 
develop a path to examine the optimal preven-
tion of stroke when there is no obvious AF. The 
benefits of oral anticoagulation for patients with 
heart failure in sinus rhythm have yet to be es-
tablished. Many cryptogenic strokes/ESUS are 
presumed to have an embolic etiology. There are 
ongoing studies: Re-SPECT ESUS, ATTICUS 
and NAVIGATE ESUS assessing the comparative 
effectiveness of OAC vs. APT in patients after 
ESUS. Further research is needed to determine 
whether anticoagulant use may reduce risk of 
recurrence in ischemic stroke patients with mod-
erate to severe left atrial enlargement and other 
potential sources of thromboembolism (Table 4). 
At present there is a lack of antithrombothic 
treatment scheme in the time between stroke 
Table 4. Potential sources of embolism and type of anti-thrombotic therapy in patients after ischemic 
stroke. 
Potential source of embolism                       Type of anti-thrombotic therapy
Established Not established
Atrial arrhythmias:
— Valvular AF x
— Non-valvular AF x
— Atrial flutter x 
(anticoagulation according  
CHADSVASC score)
Prosthetic valves and devices x 
(prostetic valve — VKA, device  
according indications)
Sinus rhythm and reduced LV function x
Patients with mitral valve prolapse who 
experience TIAs 
x (antiplatelet therapy)
Patients with mitral valve prolapsed and  
a history of stroke and mitral regurgitation, 
AF, or left atrial thrombus
x (anticoagulation)
Mitral annular calcification x
PFO/ASD without DVT x (antiplatelet therapy)
PFO/ASD with DVT x (anticoagulation)
ASA, Chiari Network, Eustachian valve, 
LAE, LASP
x
AF — atrial fibrillation; ASA — atrial septal aneurysm; ASD — atrial septal defect; DVT — deep venous thrombus; LAE — left atrial  
enlargement; LASP — left atrial septal pouch; LV — left ventricular; PFO — patent foramen ovale; TIA — transient ischemic attack;  
VKA — vitamin K antagonist
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and finishing the diagnosis of potential sources of 
thromboembolism in ESUS. It should be discussed 
if OAC therapy should not be introduced for about 
3 months during which patient could have at least 
7 days electrocardiogram monitoring, PFO and 
deep veins assessment, eventually genetic assess-
ment and based on these results a final decision on 
treatment can be stated. 
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